Foam injections to treat varicose veins cause less pain for patients and could save NHS money compared with laser therapy - News release
Imperial College London News Release
Under embargo until
9am UK time
Sunday 25 September 2011
Foam injections to treat varicose veins cause less pain for patients and could save NHS money compared with a popular alternative treatment, according to researchers at Imperial College London. The study found that foam therapy was over four times more cost-effective than laser treatment and allowed patients to resume normal activity sooner. The findings were presented today at the annual meeting of the European Society for Vascular Surgery in Athens.
Related news stories:
Varicose veins develop when the valves in veins stop working properly, causing the veins to swell. About one in three people have varicose veins when they reach retiring age, with women affected more than men. In most people, they do not present a serious health problem, but in severe cases they can cause aching, itching, swelling or leg ulcers.
Patients requiring treatment often undergo surgery to strip out the affected vein. Under general anaesthetic, the vein is tied off through a cut in the groin and pulled out by a wire passed through a cut lower in the leg. 36,209 varicose vein procedures are carried out in the NHS each year.
In the last decade, new non-surgical treatments have been introduced that cause less scarring and do not require general anaesthetic. Endovenous Laser Ablation (EVLA) involves a laser wire, inserted into the vein through a catheter, which delivers short bursts of energy that seal the vein closed. It is usually carried out under local anaesthetic. Foam sclerotherapy involves injecting foam into the vein that inflames the lining of the wall and seals the vessel.
The new study compared these two treatments in terms of benefit to the patient and cost. One hundred patients were randomly assigned to laser or foam treatment. The two treatments were found to be equally successful at closing off varicose veins. However, foam therapy procedures were more than twice as quick and cost over four times less than laser treatment on average. Patients who had foam therapy experienced less pain in the week following treatment and could return to normal activity in three days, compared with eight days for patients who had laser therapy.
Mr Christopher Lattimer, from the Department of Surgery and Cancer at Imperial College London, said: “This is the first time that anyone in the NHS has compared foam and laser treatments to see which is better value for money. We found that the cost of foam was just one quarter the cost of laser, taking into account their effectiveness. Foam treatment was also quicker, less painful, and had people back to normal activity in a shorter time.”
Mr George Geroulakos, from the Department of Surgery and Cancer at Imperial College London, said: “Because varicose veins are so common, the NHS has to spend a lot of money on treatments each year. If more people are treated with foam injections instead of surgery or laser treatment, the potential savings could be enormous. This sort of research is hugely important at a time when budgets are under such strain.”
The number of patients receiving these treatments is increasing each year, with the NHS performing 6,327 foam procedures and 6,005 EVLA procedures in England in 2009-10.
Closing the veins that run near the skin does not impair circulation as blood can still return to the heart through the larger veins inside the leg.
The research was funded by Ealing Hospital NHS Trust and STD Pharmaceuticals.
For further information please contact:
Research Media Officer
Imperial College London
Tel: +44(0)20 7594 2198
Out of hours duty press officer: +44(0)7803 886 248
Notes to editors:
1. C.R. Lattimer et al. 'Cost and Effectiveness of Laser with Phlebectomies Versus Foam Sclerotherapy in Superficial Venous Insufficiency. Early Results of a Randomised Controlled Trial.' European Society for Vascular Surgery, Athens 2011.
2. About Imperial College London
Consistently rated amongst the world's best universities, Imperial College London is a science-based institution with a reputation for excellence in teaching and research that attracts 14,000 students and 6,000 staff of the highest international quality. Innovative research at the College explores the interface between science, medicine, engineering and business, delivering practical solutions that improve quality of life and the environment - underpinned by a dynamic enterprise culture.
Since its foundation in 1907, Imperial's contributions to society have included the discovery of penicillin, the development of holography and the foundations of fibre optics. This commitment to the application of research for the benefit of all continues today, with current focuses including interdisciplinary collaborations to improve global health, tackle climate change, develop sustainable sources of energy and address security challenges.
In 2007, Imperial College London and Imperial College Healthcare NHS Trust formed the UK's first Academic Health Science Centre. This unique partnership aims to improve the quality of life of patients and populations by taking new discoveries and translating them into new therapies as quickly as possible.
Article text (excluding photos or graphics) available under an Attribution-NonCommercial-ShareAlike Creative Commons license.
Photos and graphics subject to third party copyright used with permission or © Imperial College London.
Communications and Public Affairs